ERBB2 and gastric cancer: Weekly intraperitoneal injection of trimeric DNA anti-HER2 aptamer at a dose of 40 μg exhibited a 2-fold higher tumor inhibitory effect on N87 human gastric cancer cells implanted in CD-1 mice compared to the HER2 monoclonal antibody (Ab431, 160 μg) [112].